Flerie appoints seasoned industry experts to its Board of Directors
Flerie, a global biotech and pharma investor managing over 30 companies in Europe, Israel and the US, today announced the appointment of three seasoned industry experts to join Executive Chairman Thomas Eldered on the Board of Directors. The new members are Cecilia Edström, Anders Ekblom, and Jenni Nordborg.
“The appointment of these three executives marks a new chapter in Flerie’s mission to invest in and build pioneering biotech and pharmaceutical companies. With their complementary skills and networks, we can build more strategic value in our portfolio as well as strengthen our governance. I’m excited to be working with them to achieve a significant positive impact on health and well-being,” said Thomas Eldered, Executive Chairman of Flerie.
Cecilia Edström has extensive board experience, and was most recently CEO of Bactiguard, a publicly listed medtech company. She has a corporate finance background, starting her career at SEB, and has held diverse leadership roles at Scania and Telia Sonera, the latter where she was Head of Group Communications. Cecilia holds a BSc in Finance from Stockholm School of Economics. Jenni Nordborg is Director of International Affairs at LIF, the Swedish Pharmaceuticals Trade Association, and has previously been National Coordinator for Life Sciences at the Swedish Government Offices, as well as Director at Vinnova, the Swedish Innovation Agency. She has a PhD in Inorganic Chemistry from Chalmers and has been a board member at Nordic Innovation, Linnaeus University, and Innovationsbron. Anders Ekblom spent two decades at Astra Zeneca, as EVP Global Medicines Development, Global Head Clinical Development, and CEO of Astra Zeneca AB Sweden. He has previously been Chairman of the Board of the Karolinska University Hospital and board member of the Swedish Research Council. He has an MD, PhD, DDS, and is an Associate Professor at the Karolinska Institute.
“Flerie is fulfilling a unique and important role as an active investor in pioneering life science companies and I’m looking forward to adding value by utilising my experience in scaling up both private and public enterprises, with the ultimate aim of bringing more innovative therapies to patients,” said Cecilia Edström.
“My experience from the pharma industry, academia and the health care sector has shown me the value of innovative small enterprises bringing new ideas and solutions forward. SMEs are very good at innovating, but they need long-term support and competent capital to guide them through the path to commercialisation. I’m excited to put my skills and experience to use to build on Flerie’s proven model and expand the universe of successful companies,” said Anders Ekblom.
“Thomas Eldered and the team at Flerie have built an impressive portfolio of both product development and commercial growth companies over the past 11 years and they continue to be a key player in the Swedish life science ecosystem. I’m honoured to be able to contribute with my network to help Flerie achieve its vision to be recognised as an innovative enabler of biotech solutions globally,” said Jenni Nordborg.
For more information:
Flerie Invest AB is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of over 30 companies in Europe, Israel and the US. By providing them with resources and expertise, Flerie enables pioneering technologies in the drug development and services space to accelerate on their path to treating patients. The portfolio includes a wide range of areas including immuno-oncology, metabolic diseases and biologics development and manufacturing organisations which have the potential to make a significant impact on health and wellbeing. Flerie was founded in 2011 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world’s top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.